Oct 10th 2012 - Edison Investment Research today published a report on Imperial Innovations (IVO.L, LSE:IVO, LON:IVO) entitled "No Pussyfooting Around". In summary, the report says:
Imperial Innovations’ largest bio/med portfolio company, Circassia, has started a pivotal Phase III trial of its lead allergy therapy. ToleroMune cat is the most advanced cat allergy programme in development and could reach the market by 2016. Trial initiation, data and potential regulatory filings (around end-2014) all mark significant potential value inflection points for Circassia and for Imperial Innovations through its 20.3% holding. Ahead of trial results in mid-2014, news flow is also expected in relation to Circassia’s wider pipeline of ragweed, dust mite and grass allergy products.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »